TNXP
Tonix Pharmaceuticals Holding Corp.
Set alert
- YTD
- -67.35%
- 1 year
- -71.76%
- Open
- 5.18
- Prev close
- 5.28
- Mkt cap
- 87.47M
- Vol
- 567.19K
- Avg vol
- 653.66K
- EPS
- -13.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.96
- High
- 5.29
- Forward P/E
- -0.01
- Beta
- 2.08
- Short ratio
- 0.35
- Inst. own
- 0.23%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.20
- 200-d avg
- 2.41
- 1y target
- 5.83
Key statistics
- Market cap
- 75.34M
- Enterprise value
- 8.21M
- Trailing P/E
- 0.00
- Forward P/E
- -0.01
- PEG ratio
- 0.00
- Price / sales
- 6.05
- Price / book
- 0.01
- EPS (TTM)
- -80.39
- Beta
- 2.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 12.46M
- Revenue growth
- 0.00%
- Free cash flow
- -44.01M
- Total cash
- 4.16M
- Total debt
- 9.26M
- Return on equity
- -163.24%
- Shares outstanding
- 186.89M
- Short % of float
- 5.48%
- 50-day average
- 0.20
- 200-day average
- 2.41
Analyst view
Consensus: strong buy
- Target (low)
- 2.50
- Target (mean)
- 5.83
- Target (high)
- 11.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -7.68.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -2.03 | -0.23 | +1.80 | +88.67% |
| Aug 16, 2024 | Jun 1, 2024 | -9.91 | -19.28 | -9.37 | -94.55% |
| May 13, 2024 | Mar 1, 2024 | -16.61 | -5.75 | +10.86 | +65.38% |
| Apr 1, 2024 | Dec 1, 2023 | -49.84 | -27.48 | +22.36 | +44.86% |
| Nov 9, 2023 | Sep 1, 2023 | -47.60 | -58.47 | -10.87 | -22.84% |
| Aug 10, 2023 | Jun 1, 2023 | -88.82 | -85.62 | +3.20 | +3.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 22, 2024 | Alliance Global Partners | main | Buy | Buy |
| Feb 28, 2024 | Dawson James | init | — | Buy |
| Aug 1, 2023 | Alliance Global Partners | main | Buy | Buy |
| Jun 2, 2023 | Alliance Global Partners | main | Buy | Buy |
| Aug 31, 2021 | Alliance Global Partners | main | Buy | Buy |
| Aug 11, 2021 | Alliance Global Partners | main | Buy | Buy |
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tonixpharma.com
News
- Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress
- Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
- Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18
- Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30
- Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights
Your note
Sign in to keep a note on TNXP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Millennium Management Llc | 0.19% | 361,445 | 145.70K | Sep 29, 2024 |
| UBS Group AG | 0.13% | 240,300 | 96.86K | Sep 29, 2024 |
| Virtu Financial LLC | 0.07% | 136,235 | 54.92K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.06% | 115,987 | 46.75K | Sep 29, 2024 |
| Wedbush Securities Inc | 0.02% | 40,540 | 16.34K | Sep 29, 2024 |
| LPL Financial LLC | 0.02% | 30,049 | 12.11K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.06% | 113,133 | 45.60K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 7,300 | 2.94K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 725 | 292 | Oct 30, 2024 |